302 related articles for article (PubMed ID: 36451045)
1. Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors.
Thomas AR; Liu C; Tong YT; Tan D; Altan M; Siddiqui BA; Shatila M; Khan A; Thomas AS; Wang Y
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5429-5436. PubMed ID: 36451045
[TBL] [Abstract][Full Text] [Related]
2. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis.
Abu-Sbeih H; Herrera LN; Tang T; Altan M; Chaftari AP; Okhuysen PC; Jenq RR; Wang Y
J Immunother Cancer; 2019 Sep; 7(1):242. PubMed ID: 31488205
[TBL] [Abstract][Full Text] [Related]
3. Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis.
Grover S; Ruan AB; Srivoleti P; Giobbie-Hurder A; Braschi-Amirfarzan M; Srivastava A; Buchbinder EI; Ott PA; Kehl KL; Awad MM; Hodi FS; Rahma OE
JCO Oncol Pract; 2020 Sep; 16(9):e933-e942. PubMed ID: 32401685
[TBL] [Abstract][Full Text] [Related]
4. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis.
Abu-Sbeih H; Ali FS; Wang X; Mallepally N; Chen E; Altan M; Bresalier RS; Charabaty A; Dadu R; Jazaeri A; Lashner B; Wang Y
J Immunother Cancer; 2019 Apr; 7(1):93. PubMed ID: 30940209
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis.
Grover S; Dougan M; Tyan K; Giobbie-Hurder A; Blum SM; Ishizuka J; Qazi T; Elias R; Vora KB; Ruan AB; Martin-Doyle W; Manos M; Eastman L; Davis M; Gargano M; Haq R; Buchbinder EI; Sullivan RJ; Ott PA; Hodi FS; Rahma OE
Cancer; 2020 Aug; 126(16):3758-3767. PubMed ID: 32567084
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
8. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y
J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161
[TBL] [Abstract][Full Text] [Related]
9. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
10. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
[TBL] [Abstract][Full Text] [Related]
11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
12. Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment.
Pizuorno Machado A; Shatila M; Glitza Oliva IC; Altan M; Siddiqui B; Zhou Y; Varatharajalu K; Zhang HC; Thomas A; Wang Y
Am J Clin Oncol; 2023 Aug; 46(8):360-365. PubMed ID: 37219360
[TBL] [Abstract][Full Text] [Related]
13. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after sustained disease control.
Sharma H; Moturi KR; Pankratz VS; Yilmaz E; Gbolahan OB; Kumar A; Hashemi-Sadraei N
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8673-8680. PubMed ID: 37115270
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study.
Abu-Sbeih H; Ali FS; Alsaadi D; Jennings J; Luo W; Gong Z; Richards DM; Charabaty A; Wang Y
J Immunother Cancer; 2018 Dec; 6(1):142. PubMed ID: 30518410
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
[TBL] [Abstract][Full Text] [Related]
17. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.
Abu-Sbeih H; Ali FS; Naqash AR; Owen DH; Patel S; Otterson GA; Kendra K; Ricciuti B; Chiari R; De Giglio A; Sleiman J; Funchain P; Wills B; Zhang J; Naidoo J; Philpott J; Gao J; Subudhi SK; Wang Y
J Clin Oncol; 2019 Oct; 37(30):2738-2745. PubMed ID: 31163011
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies.
Tran AN; Wang M; Hundt M; Chugh R; Ohm J; Grimshaw A; Ciarleglio M; Hung KW; Proctor DD; Price CC; Laine L; Al-Bawardy B
J Immunother; 2021 Oct; 44(8):325-334. PubMed ID: 34380976
[TBL] [Abstract][Full Text] [Related]
19. Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
Torasawa M; Yoshida T; Takeyasu Y; Shimoda Y; Tateishi A; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y
Cancer Med; 2023 Jun; 12(11):12388-12401. PubMed ID: 37062059
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
